SP-A and PGF2α: Physiological Role and Clinical Application
Surfactant protein A (SP-A) acts as a natural brake on labor by selectively inhibiting prostaglandin F2α (PGF2α) production in the decidua, and its decline at term permits the rise in PGF2α that drives uterine contractions and labor onset. 1
Physiological Mechanism
SP-A is produced by human endometrium and decidua, where it plays a critical regulatory role in prostaglandin metabolism. The key findings demonstrate:
- Selective inhibition: High-dose SP-A (100 μg/ml) significantly and selectively inhibits PGF2α production by term decidual stromal cells without affecting other inflammatory mediators (IL-6, IL-8, TNFα, PGE2) 1
- Posttranscriptional regulation: This inhibitory effect occurs at a posttranscriptional level, not through gene expression changes 1
- Labor-associated decline: Decidual SP-A expression decreases significantly with the onset of labor, removing this inhibitory brake 1
This mechanism suggests SP-A functions as a gatekeeper that maintains uterine quiescence during pregnancy by suppressing PGF2α. When SP-A levels fall at term, PGF2α production increases, triggering "decidual activation" and labor initiation.
Role of PGF2α in Parturition
PGF2α serves as a final common mediator of labor across all species 2:
- Myometrial contraction: PGF2α consistently stimulates strong, sustained myometrial contractions, unlike PGE2 which produces biphasic effects (initial contraction followed by relaxation) 3
- Labor accomplishment: While PGE2 may be more important for labor onset and cervical ripening, PGF2α plays the dominant role in labor accomplishment through sustained uterine contractions 3
- COX enzyme dependence: PGF2α production requires cyclooxygenase (COX) enzymes, with COX-2 expression reaching maximum levels at delivery 2
Clinical Application: Carboprost Tromethamine
Carboprost tromethamine (15-methyl-PGF2α analog) is FDA-approved and clinically used as a second-line uterotonic for postpartum hemorrhage when oxytocin fails. 4, 5
Mechanism of Action
Carboprost stimulates myometrial contractions similar to full-term labor contractions, providing hemostasis at the placentation site postpartum 4. Peak plasma concentrations occur at 15-30 minutes after intramuscular injection (approximately 2,000-3,000 picograms/mL) 4.
Clinical Indications and Dosing
- Postpartum hemorrhage: 250 mcg intramuscularly, may repeat at intervals 4, 5
- Intrauterine fetal demise: Effective for labor induction with 93.75% success rate 6
- Second-line therapy: Used when persistent bleeding occurs despite oxytocin treatment 5
Clinical Outcomes
Evidence demonstrates carboprost combined with oxytocin:
- Significantly reduces 2-hour bleeding (256.7±65.21 mL) and 24-hour hemorrhage (308.3±78.3 mL) compared to oxytocin alone 7
- Improves uterine involution with faster uterine floor descent and shorter lochia duration 8
- Maintains hemodynamic stability (SBP 119.4±8.24 mmHg, DBP 79.6±6.21 mmHg) 7
- Reduces neonatal ICU admission rates and improves Apgar scores 8
Important Caveats
- Side effects: Can cause gastrointestinal symptoms (vomiting, diarrhea), transient temperature elevation, and potential bronchoconstriction 4
- Cardiovascular effects: Large doses may elevate blood pressure through vascular smooth muscle contraction, though not clinically significant at therapeutic doses 4
- Adjuvant medication: Prophylactic administration of analgesics, anti-emetics, and anti-diarrheals improves tolerance 6
- Off-target activation: Carboprost can activate the closely related EP3 receptor, causing side effects that limit clinical application 9
Comparison to Other Prostaglandins
Unlike PGE2 analogs (misoprostol, dinoprostone) used primarily for cervical ripening and labor induction 10, carboprost's consistent contractile effect makes it specifically suited for hemorrhage control rather than labor induction in viable pregnancies.
Key clinical pearl: The physiological decline of SP-A at term that permits PGF2α rise explains why exogenous PGF2α analogs (carboprost) are so effective postpartum—they mimic the natural surge that should occur but may be insufficient in cases of uterine atony.